
Stereotactic body radiotherapy for kidney cancer: a 10-year experience from a single institute
Author(s) -
Takaya Yamamoto,
Yoshihide Kawasaki,
Rei Umezawa,
Noriyuki Kadoya,
Haruo Matsushita,
Kazuya Takeda,
Yojiro Ishikawa,
Noriyoshi Takahashi,
Yu Suzuki,
Ken Takeda,
Kohsuke Kawabata,
Akihiro Ito,
Keiichi Jingu
Publication year - 2021
Publication title -
journal of radiation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.643
H-Index - 60
eISSN - 1349-9157
pISSN - 0449-3060
DOI - 10.1093/jrr/rrab031
Subject(s) - medicine , log rank test , survival rate , cancer , retrospective cohort study , radiation therapy , kidney cancer , nuclear medicine , oncology , urology , overall survival , surgery , radiology
The purpose of this retrospective study was to investigate survival outcomes and irradiated tumor control (local control [LC]) and locoregional control (LRC) after stereotactic body radiotherapy (SBRT) for T1 or recurrent T1 (rT1) kidney cancer. Twenty-nine nonconsecutive patients with 30 tumors were included. SBRT doses of 70 Gy, 60 Gy or 50 Gy in 10 fractions were prescribed with a linear accelerator using daily image guidance. The Kaplan-Meier method was used to estimate time-to-event outcomes, and the log-rank test was used to compare survival curves between groups divided by each possible factor. The median follow-up periods for all patients and survivors were 57 months and 69.6 months, respectively. The five-year LC rate, LRC rate, progression-free survival (PFS) rate, disease-specific survival (DSS) rate and overall survival (OS) rate were 94%, 88%, 50%, 96% and 68%, respectively. No significant factor was related to OS and PFS. Three of 24 non-hemodialysis (HD) patients had new-onset-HD because of the progression of underlying kidney disease. Grade 3 or higher toxicities from SBRT did not occur. In conclusion, SBRT for kidney cancer provided a high rate of LC, LRC and DSS with minimal toxicities, but patient selection and indication for SBRT should be done carefully considering the relatively low OS rate.